Read the original post:
Faron Pharmaceuticals Notice of Half-Year Financial Results
Related Post
- Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress - May 25th, 2024
- Minutes of Annual General Meeting 2024 - May 25th, 2024
- Monopar Announces CFO Succession - May 25th, 2024
- BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid... - May 25th, 2024
- IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024 - May 25th, 2024
- Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit - May 25th, 2024
- Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy - May 25th, 2024
- Scilex Holding Company Sends Letter to U.S. House of Representatives on Illegal Market Manipulation of the Common Stock of Scilex Holding Company - May 25th, 2024
- BioSenic provides First Quarter 2024 Business Update - May 25th, 2024
- Purespring Therapeutics presents preclinical data at the 61st ERA Congress - May 25th, 2024
- Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress - May 25th, 2024
- Scilex Holding Company Announces it has been Added to the MSCI Global Microcap Index - May 25th, 2024
- Guerbet : Hugues Lecat appointed Chairman of the Board of Directors of Guerbet. - May 25th, 2024
- Iovance Biotherapeutics to Present at Upcoming Conferences and Events - May 25th, 2024
- Sobi Receives US FDA Fast Track Designation for Emapalumab-lzsg being investigated in Macrophage Activation Syndrome - May 25th, 2024
- Sobi to present new myelofibrosis data at the ASCO 2024 Annual Meeting - May 25th, 2024
- OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q - May 25th, 2024
- Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio - May 25th, 2024
- Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically... - May 25th, 2024
- Rakovina Therapeutics Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations - May 25th, 2024
- Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in... - May 23rd, 2024
- Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting - May 23rd, 2024
- Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in... - May 23rd, 2024
- Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting - May 23rd, 2024
- IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting - May 23rd, 2024
- Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid... - May 23rd, 2024
- Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress - May 23rd, 2024
- Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024... - May 23rd, 2024
- HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting - May 23rd, 2024
- Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in... - May 23rd, 2024
- Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be... - May 23rd, 2024
- BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology... - May 23rd, 2024
- Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated... - May 23rd, 2024
- NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of... - May 23rd, 2024
- I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024 - May 23rd, 2024
- Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the... - May 23rd, 2024
- FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with... - May 23rd, 2024
- Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer - May 23rd, 2024
- Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting - May 23rd, 2024
- G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting - May 23rd, 2024
- BioSyent Releases Financial Results for Q1 2024 - May 19th, 2024
- BioSyent Declares Second Quarter 2024 Dividend - May 19th, 2024
- HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress - May 19th, 2024
- Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise - May 19th, 2024
- Chemomab Therapeutics to Participate in Upcoming Scientific Conferences - May 19th, 2024
- QuTEM Receives GMP Certificates and Manufacturing Permits for Transmission Electron Microscopy Laboratory from the Swedish Medical Products Agency - May 19th, 2024
- Telix Files Registration Statement for Proposed Initial Public Offering in the United States - May 19th, 2024
- Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company Showcase - May 19th, 2024
- Tilray Brands Announces At-The-Market Program to Fund Strategic and Accretive Acquisitions and Accelerate Expansion Plan Upon U.S. Cannabis... - May 19th, 2024
- Intercept Presents New Data Demonstrating the Impact of OCA-Bezafibrate Combination Therapy on ALP and Metabolic Outcomes After Six Months of... - May 19th, 2024
- Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET - May 19th, 2024
- Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine - May 18th, 2024
- Recce Pharmaceuticals Doses First Participants in Next Cohort of Phase I/II Urinary Tract Infections and Urosepsis Rapid Infusion Clinical Trial - May 18th, 2024
- Aeterna Zentaris Announces Details Regarding Transaction with Ceapro - May 18th, 2024
- Innovative Fingerprint Drug Screening Solution Showcased at the UK's Premier Health and Safety Event - May 18th, 2024
- Achieve Life Sciences Announces Data from Cytisinicline ORCA-V1 Program to be Presented at Society of General Internal Medicine (SGIM) Annual Meeting - May 18th, 2024
- Spectral AI Announces Purchases of Over 100,000 Shares by Insiders - May 18th, 2024
- HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees - May 18th, 2024
- Assertio to Participate in Benchmark Healthcare Conference on May 21-22 - May 18th, 2024
- Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ - May 18th, 2024
- BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024 - May 18th, 2024
- More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024 - May 18th, 2024
- Better Choice Company Announces First Quarter 2024 Results - May 18th, 2024
- Recludix Pharma Presents Data Demonstrating Oral STAT3 Inhibitors Drive Differentiated Efficacy and Safety in Preclinical Models of Th17 Mediated Skin... - May 18th, 2024
- Kamari Pharma Announces New Data Presented at the 81st Annual Meeting of the Society for Investigative Dermatology - May 18th, 2024
- NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations - May 18th, 2024
- DBV Technologies Announces Plan to Implement ADS Ratio Change - May 18th, 2024
- Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day - May 18th, 2024
- Plus Therapeutics Announces New Employment Inducement Grants - May 18th, 2024
- Oculis updates share capital for its existing at-the-market offering program - May 18th, 2024
- Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action - May 18th, 2024
- Kane Biotech Expands its Wound Care Portfolio with Patented Schultz Biofilm Wound Map - May 15th, 2024
- Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member - May 15th, 2024
- Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia - May 15th, 2024
- Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024 - May 15th, 2024
- CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates - May 15th, 2024
- Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates - May 15th, 2024
- Tonix Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase - May 15th, 2024
- Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update - May 15th, 2024
- Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis - May 15th, 2024
Recent Comments